Patents by Inventor Wendy L. Trigona

Wendy L. Trigona has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of using antibody polypeptides that antagonize CD40 to treat IBD
    Patent number: 10435475
    Abstract: A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: October 8, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Marek Honczarenko, Vaishali Shah, Xiaoni Liu, Wendy L. Trigona, Rong Shi, Suzanne J. Suchard, Karen D. Price, Linda M. Gustavson
  • METHOD OF USING ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40 TO TREAT IBD
    Publication number: 20160355596
    Abstract: A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.
    Type: Application
    Filed: March 9, 2015
    Publication date: December 8, 2016
    Inventors: Marek HONCZARENKO, Shah VAISHALI, Xiaoni LIU, Wendy L. TRIGONA, Rong SHI, Suzanne J. SUCHARD, Karen D. PRICE, Linda M. GUSTAVSON
  • IP-10 antibody dosage escalation regimens
    Patent number: 9429581
    Abstract: In certain embodiments, the present invention provides a method of treating an Interferon gamma inducible protein 10 (IP-10)-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IP-10 antibody; (b) detecting the level of the anti-IP-10 antibody in a sample of the subject; and (c) if the level of the anti-IP-10 antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IP-10 antibody in the subject such that the IP-10 related disease in the subject is treated. In certain embodiments, the present invention provides an isolated monoclonal anti-idiotypic antibody, or an antigen binding portion thereof, which binds to the anti-IP-10 antibody MDX-1100.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: August 30, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Allison Y. Luo, Wendy L. Trigona, Jinshan Shen, Li-An Xu, Yan Zhang, Bruce Stouffer, Haibin Chen, Haichun Huang, Xiaolu Tao, Catherine Brockus
  • IP-10 ANTIBODY DOSAGE ESCALATION REGIMENS
    Publication number: 20140127229
    Abstract: In certain embodiments, the present invention provides a method of treating an IP-10-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IP-10 antibody; (b) detecting the level of the anti-IP-10 antibody in a sample of the subject; and (c) if the level of the anti-IP-10 antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IP-10 antibody in the subject such that the IP-10 related disease in the subject is treated. In certain embodiments, the present invention provides an isolated monoclonal anti-idiotypic antibody, or an antigen binding portion thereof, which binds to the anti-IP-10 antibody MDX-1100.
    Type: Application
    Filed: October 16, 2013
    Publication date: May 8, 2014
    Inventors: Allison Y. Luo, Wendy L. Trigona, Jinshan Shen, Li-An Xu, Yan Zhang, Bruce Stouffer, Haibin Chen, Haichun Huang, Xiaolu Tao, Catherine Brockus
  • IP-10 ANTIBODY DOSAGE ESCALATION REGIMENS
    Publication number: 20140065164
    Abstract: In certain embodiments, the present invention provides a method of treating an IP10-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IPIO antibody; (b) detecting the level of the anti-IPIO antibody in a sample of the subject; and (c) if the level of the anti-IPIO antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IPIO antibody in the subject such that the IP-10 related disease in the subject is treated.
    Type: Application
    Filed: April 27, 2012
    Publication date: March 6, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Allison Y. Luo, Wendy L. Trigona, Jinshan Shen, Li-An Xu, Yan Zhang, Bruce Stouffer, Haibin Chen, Haichun Huang, Xiaolu Tao, Catherine Brockus